Bipinchandra Bhagat, MD
Infectious Disease · Victorville, CANPI 1306046123
Payments from drug & device makers
Across 458 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Viiv Healthcare Company$1K
- Johnson & Johnson$1K
- Melinta Therapeutics, LLC$1K
- AbbVie$1K
- Smith+Nephew$417
- plus $2K from 29 others
What the payments were for
- Food & beverage$8,14396%
- Education$3064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 78 | $1,389 |
| Viiv Healthcare Company | 58 | $1,141 |
| Johnson & Johnson(2 entities) | 64 | $1,128 |
| Melinta Therapeutics, LLC | 47 | $1,049 |
| AbbVie(2 entities) | 70 | $1,012 |
| Smith+Nephew | 21 | $417 |
| Sanofi-aventis U.S. LLC | 18 | $318 |
| Gilead | 27 | $294 |
| Janssen Products, LP | 4 | $241 |
| Lilly USA, LLC | 12 | $230 |
| Shionogi Inc | 5 | $124 |
| AstraZeneca | 6 | $121 |
| Boehringer Ingelheim | 6 | $117 |
| Novo Nordisk | 5 | $92 |
| Sun Pharmaceutical Industries Inc. | 1 | $85 |
| Biohaven Pharmaceuticals, Inc. | 4 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Organogenesis Inc. | 4 | $52 |
| Integra Lifesciences Corporation | 2 | $45 |
| EMD Serono, Inc. | 2 | $45 |
| Insmed, Inc. | 2 | $41 |
| Amgen | 2 | $36 |
| Insulet Corporation | 2 | $36 |
| Polarityte, Inc. | 1 | $36 |
| Vertiflex, Inc. | 1 | $34 |
| Pfizer | 2 | $33 |
| Cumberland Pharmaceuticals, Inc. | 2 | $30 |
| Theratechnologies Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Convatec Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Next Science LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,449 in reported general payments places this provider in the 75th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 158 | $642,484 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 63 | $309,049 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 83 | $308,592 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 43 | $176,166 |
| DovatoDolutegravir Sodium/Lamivudine | 28 | $81,133 |
| TivicayDolutegravir Sodium | 23 | $38,111 |
| JulucaDolutegravir/Rilpivirine | 12 | $37,487 |
| SantylCollagenase Clostridium Hist. | 24 | $34,562 |
| JanuviaSitagliptin Phosphate | 46 | $33,892 |
| TrulicityDulaglutide | 34 | $31,981 |
| Daptomycin | 95 | $30,875 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,365 |
| JardianceEmpagliflozin | 37 | $24,041 |
| OzempicSemaglutide | 24 | $21,937 |
| XareltoRivaroxaban | 18 | $18,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $294 | $847,015214 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Juluca | $1,141 | $465,323146 claims |
| Janssen Products, LPSymtuza | $241 | $309,04963 claims |
| MerckJanuvia, Janumet, Belsomra | $1,389 | $52,90177 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $230 | $46,52848 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $117 | $36,78261 claims |
| Smith+NephewSantyl | $417 | $34,56224 claims |
| Novo NordiskOzempic | $92 | $21,93724 claims |
| Johnson & JohnsonXarelto | $1,128 | $18,05918 claims |
| GSKAnoro Ellipta | $23 | $11,98320 claims |
| AstraZenecaSymbicort | $121 | $2,27411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 856 infectious disease providers in California.
Other infectious disease in Victorville
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- James McKinnellTorrance$4.3M
- Loren MillerTorrance$4.1M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.